



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*(Use as many sheets as necessary)*

Sheet	1	of	4
-------	---	----	---

Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

[illegible]

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	1 <sup>5</sup>
			MM-DD-YYYY			
		Country Code <sup>2</sup> Number <sup>4</sup> Kind Code <sup>3</sup> (if known)				
DB	4	WO 02/100330	12-19-2002	Abbott Biotechnology Ltd.		
DB	5	WO 04/004633	01-15-2004	Abbott Biotechnology Ltd.		
DB	6	WO 04/016286	02-26-2004	Abbott Biotechnology Ltd.		
DB	7	WO 04/037205	05-06-2004	Abbott Biotechnology Ltd.		
DB	8	WO 97/29131	08-14-1997	BASF Aktiengesellschaft		

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		Aloe et al., "Role of TNF-alpha but not NGF in murine hyperalgesia induced by parasitic infection". Psychopharmacology (Berl). 1997 Dec; 134(3): 287-292.	
		Bennett and Xie, "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man". (1988) Pain. 33: 87-107.	
		Coelho et al., "Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve". Am J Physiol Gastrointest Liver Physiol. 2000 Oct; 279(4): G781-G790.	
		Coelho et al., "Brain interleukin-1 $\beta$ and tumor necrosis factor- $\alpha$ are involved in lipopolysaccharide-induced delayed rectal allodynia in awake rats". Brain Res Bull 2000 June, 52(3): 223-228.	
		Cunha et al., "The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia." Br J Pharmacol. 1992 Nov., 107(3): 660-664.	
		Empl et al., Neurology. "TNF-alpha expression in painful and nonpainful neuropathies." 2001 May 22; 56(10): 1371-1377.	
		Huygen et al., "Evidence for local inflammation in complex regional pain syndrome type 1." Mediators Inflamm. 2002 Feb;11(1): 47-51.	
		Ignatowski et al., "Brain-derived TNFalpha mediates neuropathic pain." Brain Res. 1999 Sep 11; 841(1-2): 70-77.	
		Kim and Chung, "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat." (1992) Pain 50: 355-363	
DB		Lindenlaub and Sommer, "Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies." (2003) Acta Neuropathol (Berl). 105:593	

Examiner Signature	/David Blanchard/	Date Considered	08/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

Sheet

3

of

4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		Lindenlaub et al., "Effects of neutralizing antibodies to TNF $\alpha$ on pain-related behavior and nerve regeneration in mice with chronic constriction injury." Brain Res. 2000 Jun 2; 866(1-2): 15-22.	
		Myers, R., "The Pathogenesis of Neuropathic Pain." Regional Anesthesia (1995) 20(3):173-184.	
		Old, L., "Tumor Necrosis Factor (TNF)." (1985) Science 230: 630-632	
		Olmarker et al., "Selective Inhibition of Tumor Necrosis Factor- $\alpha$ Prevents Nucleus Pulposus-Induced Thrombus Formation, Intraneural Edema, and Reduction of Nerve Conduction Velocity." Spine. 2001 Apr 15; 26(8): 863-869.	
		Parada et al., "Tumor necrosis factor receptor type-1 in sensory neurons contributes to induction of chronic enhancement of inflammatory hyperalgesia in rat." Eur J Neurosci. 2003 May; 17(9): 1847-1852.	
		Sagara et al., "Inhibition of development of peripheral neuropathy in streptozotocin-induced diabetic rats with N-acetylcysteine." Diabetologia. 1996 Mar; 39(3): 263-269.	
		Schafers et al., "Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor- $\alpha$ and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice." Neurosci Lett. 2001 Sep 14; 310(2-3): 113-116.	
		Schafers et al., "Increased Sensitivity of Injured and Adjacent Uninjured Rat Primary Sensory Neurons to Exogenous Tumor Necrosis Factor $\alpha$ after Spinal Nerve Ligation J Neurosci. 2003 Apr 1; 23(7): 3028-3038.	
		Sommer et al., "Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy." Brain Res. 2001 Sep 14; 913(1): 86-89.	
DB		Sommer et al., "Etanercept reduces hyperalgesia in experimental painful neuropathy." J Peripher Nerv Syst. 2001 Jun; 6(2): 67-72.	

Examiner Signature	/David Blanchard/	Date Considered	08/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form, to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/623,035
Filing Date	July 18, 2003
First Named Inventor	S. Banerjee
Art Unit	1643
Examiner Name	David J. Blanchard
Attorney Docket Number	BBC-206

Sheet

4

of

4

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DB		Sommer et al., "Hyperalgesia in Experimental Neuropathy Is Dependent on the TNF Receptor 1." Exp Neurol. 1998 May; 151(1):138-142	
		Sommer, C. "Animal studies on neuropathic pain: the role of cytokines and cytokine receptors in pathogenesis and therapy." Schmerz . (1999) 13(5): 315-323.	
		Sorkin et al., "Tumour necrosis factor-alpha induces extopic activity in nociceptive primary afferent fibres." Neuroscience. 1997 Nov; 81(1): 255-262.	
		Watkins et al., "Characterization of cytokine-induced hyperalgesia." Brain Res. 1994 Aug 15; 654(1): 15-26.	
DB		Zimmermann, "Pathobiology of neuropathic pain." Eur J Pharmacol. 2001 Oct 19; 429(1-3): 23-37.	

Examiner Signature	/David Blanchard/	Date Considered	08/01/2006
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.